Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 4248

1.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group..

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
2.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.

Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.

PMID:
20014981
3.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
4.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
5.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
6.

[Pharmacoeconomic review of the use of injectable long-acting risperidone].

Bartkó G, Fehér L.

Neuropsychopharmacol Hung. 2005 Dec;7(4):199-207. Review. Hungarian.

PMID:
16496485
7.

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.

Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS; e-STAR Study Group..

Curr Med Res Opin. 2009 Sep;25(9):2197-206. doi: 10.1185/03007990903149306.

PMID:
19604073
8.

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Chue PS, Heeg B, Buskens E, van Hout BA.

Pharmacoeconomics. 2005;23 Suppl 1:62-74.

PMID:
16416762
9.
10.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
11.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
12.

Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Carswell C, Wheeler A, Vanderpyl J, Robinson E.

Clin Drug Investig. 2010;30(11):777-87. doi: 10.2165/11537680-000000000-00000.

PMID:
20712387
13.

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.

Leal A, Rosillon D, Mehnert A, Jarema M, Remington G.

Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):811-6.

PMID:
15386706
14.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

15.

Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.

Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH; CSP 555 Research Group..

Clin Trials. 2011 Apr;8(2):196-204. doi: 10.1177/1740774510392931.

PMID:
21270143
16.
17.

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.

J Clin Psychiatry. 2003 Oct;64(10):1250-7.

PMID:
14658976
18.

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.

Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout BA.

Curr Med Res Opin. 2008 Feb;24(2):349-58.

PMID:
18081988
19.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
20.

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Frey S, Linder R, Juckel G, Stargardt T.

Eur J Health Econ. 2014 Mar;15(2):133-42. doi: 10.1007/s10198-013-0460-9.

PMID:
23420082
Items per page

Supplemental Content

Support Center